Diligence memo · auto-generated · as of July 2, 2026
Synapticure, Inc.
Synapticure, Inc. has raised $40M over 1 round; too few niche peers to rank its valuation yet.
Businessfiled
Synapticure, Inc. operates in Biotech, based in CHICAGO, IL, USA; Remote. We deliver personalized medicine for neurodegenerative patients
Sub-sector tags: Digital Health, Health Tech, Healthcare, Mental Health, Telehealth, biotech, healthtech, insurance.
Capital & rounds (filed)filed
Synapticure, Inc. has raised $40M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $40M on 2024-09-09.
Most recent recorded round closed around 2024-09-09.
Valuation (modeled)modeled
Provath models Synapticure, Inc. at approximately $333M (range $124M–$493M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Too few comparable companies in this niche to rank the valuation fairly yet.
Financing rhythm & timingmixed
Last raise 22 mo ago; this sector typically re-raises about every 11 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
Comparablesmixed
Capital scale ranks ahead of 96% of Biotech peers (233 compared).
Modeled value ranks above 96% of those peers.
Peoplefiled
7 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.